World's Best Scientists 2026 revealed!
Award Badge
Microbiology
Argentina
2026

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Microbiology 66 2362 2161 1 1 309 19480

Pedro Cahn publications per year

The chart shows the history of publications by Pedro Cahn between 1982 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Pedro Cahn published across 44 years, from 1982 to 2025, averaging 8.2 papers a year. Output peaked at 24 publications in 2008. 21 of the 359 publications appeared in the last two years.

No. of publications
5 10 15 20
Bar chart. Horizontal axis: year, 1982 to 2025. Vertical axis: number of publications, 0 to 24. Peak 24 publications in 2008. 1982: 1 publication 1983: 1 publication 1984: 1 publication 1985: 1 publication 1986: 0 publications 1987: 1 publication 1988: 3 publications 1989: 0 publications 1990: 1 publication 1991: 1 publication 1992: 3 publications 1993: 2 publications 1994: 1 publication 1995: 1 publication 1996: 1 publication 1997: 5 publications 1998: 0 publications 1999: 4 publications 2000: 7 publications 2001: 2 publications 2002: 9 publications 2003: 10 publications 2004: 17 publications 2005: 10 publications 2006: 10 publications 2007: 13 publications 2008: 24 publications 2009: 4 publications 2010: 16 publications 2011: 13 publications 2012: 20 publications 2013: 14 publications 2014: 20 publications 2015: 12 publications 2016: 14 publications 2017: 8 publications 2018: 18 publications 2019: 13 publications 2020: 13 publications 2021: 18 publications 2022: 13 publications 2023: 13 publications 2024: 10 publications 2025: 11 publications
1982 2025

359 publications in total across all disciplines

View publications per year as a table
Pedro Cahn: publications per year, 1982 to 2025
Year Publications
1982 1
1983 1
1984 1
1985 1
1986 0
1987 1
1988 3
1989 0
1990 1
1991 1
1992 3
1993 2
1994 1
1995 1
1996 1
1997 5
1998 0
1999 4
2000 7
2001 2
2002 9
2003 10
2004 17
2005 10
2006 10
2007 13
2008 24
2009 4
2010 16
2011 13
2012 20
2013 14
2014 20
2015 12
2016 14
2017 8
2018 18
2019 13
2020 13
2021 18
2022 13
2023 13
2024 10
2025 11
Total 359
Download as CSV

Pedro Cahn publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Pedro Cahn sits on this spectrum.

No. of scientists
50 100 150 200 250
Bar chart with 64 bars. Horizontal axis: publications, 55–64 to 679+. Vertical axis: number of scientists, 0 to 288. Most scientists, 288, have 135–144 publications. The last bar groups every scientist with 679 publications or more. The highlighted bar, 305–314 publications, is where this scientist sits. 55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55–64 publications 679+

This scientist: 309 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

View publications distribution as a table
Number of Microbiology scientists by publication count, Research.com 2026 ranking edition. Based on 5,513 ranked scientists.
Publications Scientists This scientist
55–64 8
65–74 29
75–84 55
85–94 112
95–104 137
105–114 190
115–124 235
125–134 234
135–144 288
145–154 265
155–164 264
165–174 253
175–184 276
185–194 190
195–204 234
205–214 208
215–224 198
225–234 155
235–244 161
245–254 160
255–264 146
265–274 139
275–284 148
285–294 115
295–304 96
305–314 88 309
315–324 106
325–334 65
335–344 76
345–354 64
355–364 62
365–374 65
375–384 61
385–394 34
395–404 44
405–414 36
415–424 35
425–434 29
435–444 33
445–454 34
455–464 25
465–474 26
475–484 20
485–494 19
495–504 16
505–514 17
515–524 23
525–534 14
535–544 14
545–554 18
555–564 12
565–574 7
575–584 9
585–594 9
595–604 9
605–614 7
615–624 9
625–634 7
635–644 4
645–654 5
655–664 6
665–674 7
675–678 3
679+ 99
Download as CSV

Pedro Cahn D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Pedro Cahn sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 88 bars. Horizontal axis: D-Index, 40 to 127+. Vertical axis: number of scientists, 0 to 162. Most scientists, 162, have 58 D-Index. The last bar groups every scientist with 127 D-Index or more. The highlighted bar, 66 D-Index, is where this scientist sits. 40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 66 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

View D-Index distribution as a table
Number of Microbiology scientists by D-index, Research.com 2026 ranking edition. Based on 5,513 ranked scientists.
D-Index Scientists This scientist
40 30
41 86
42 90
43 117
44 122
45 123
46 108
47 110
48 106
49 109
50 129
51 111
52 116
53 127
54 134
55 134
56 112
57 136
58 162
59 151
60 139
61 123
62 126
63 144
64 109
65 103
66 124 66
67 112
68 103
69 131
70 94
71 93
72 96
73 92
74 80
75 66
76 87
77 60
78 73
79 59
80 57
81 55
82 47
83 77
84 50
85 45
86 42
87 41
88 32
89 38
90 35
91 34
92 27
93 26
94 33
95 22
96 37
97 22
98 21
99 22
100 30
101 16
102 20
103 17
104 19
105 16
106 19
107 18
108 14
109 10
110 9
111 7
112 11
113 6
114 15
115 10
116 12
117 7
118 10
119 10
120 11
121 2
122 7
123 12
124 5
125 9
126 6
127+ 95
Download as CSV

Research.com Recognitions

  • 2026 - Research.com Microbiology in Argentina Leader Award
  • 2025 - Research.com Microbiology in Argentina Leader Award

Overview

Pedro Cahn is affiliated with the University of Buenos Aires in Argentina. Their research primarily focuses on the field of Medicine, with a strong emphasis on Infectious Diseases, Virology, Epidemiology, Emergency Medicine, and Public Health, Environmental and Occupational Health.

The scientist has contributed extensively to several main topics of work, including:

  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • HIV, Drug Use, Sexual Risk
  • SARS-CoV-2 and COVID-19 Research
  • LGBTQ Health, Identity, and Policy

Pedro Cahn has published numerous papers in notable journals. Some of the recent publications include:

  • "Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression" (2020) in New England Journal of Medicine
  • "Mpox in people with advanced HIV infection: a global case series" (2023) in The Lancet
  • "Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial" (2021) in The Lancet
  • "Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection" (2020) in New England Journal of Medicine
  • "Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV" (2021) in Nature Communications

Frequent co-authors who have collaborated with Pedro Cahn include:

  • Omar Sued
  • María Inés Figueroa
  • María José Rolón
  • Jean-Michel Molina
  • Diego Cecchini

The scientist's research has appeared most frequently in the following publication venues:

  • Actualizaciones en Sida e Infectología
  • The Lancet HIV
  • SSRN Electronic Journal
  • New England Journal of Medicine
  • UNC Libraries

Best Publications

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

    F van Leth;P Phanuphak;K Ruxrungtham;E Baraldi

  • Antiretroviral Treatment of Adult HIV Infection

    Scott M. Hammer;Joseph J. Eron;Peter Reiss;Robert T. Schooley

  • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

    Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson

  • Antiretroviral Treatment of Adult HIV Infection

    Unknown

  • Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

    Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  • Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

    Unknown

  • Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

    Susan Swindells;Jaime-Federico Andrade-Villanueva;Gary J. Richmond;Giuliano Rizzardini

  • Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

    Pedro Cahn;Anton L Pozniak;Horacio Mingrone;Andrey Shuldyakov

  • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

    Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley

  • Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    Unknown

  • Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration

    Rami Kantor;David A Katzenstein;Brad Efron;Ana Patricia Carvalho

  • Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

    Unknown

  • Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

    Frank van Leth;Prahpan Phanuphak;Erik Stroes;Brian Gazzard

  • Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

    Robert Leo Murphy;Ian Sanne;Pedro Cahn;Praphan Phanuphak

  • Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

    Calvin J. Cohen;Jean-Michel Molina;Pedro Cahn;Bonaventura Clotet

  • Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.

    Xavier Saez-Llorens;Avyi Violari;Carl O. Deetz;Richard A. Rode

  • Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.

    Michael S. Saag;Pedro Cahn;François Raffi;Marcelo Wolff

  • Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

    Pedro Cahn;Jaime Andrade-Villanueva;José R Arribas;José M Gatell

  • A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

    Daniel Podzamczer;Elena Ferrer;Ezequiel Consiglio;José Maria Gatell

  • G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate.

    Laura Rodero;Emilia Mellado;A Carolina Rodriguez;Angela Salve

  • Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme

    Catherine C McGowan;Pedro Cahn;Eduardo Gotuzzo;Denis Padgett

  • Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

    Ulrik B.Ulrik Dragsted;Jan Gerstoft;Court Pedersen;Barry Peters

  • Discontinuation of Maintenance Therapy for Cryptococcal Meningitis in Patients with AIDS Treated with Highly Active Antiretroviral Therapy: An International Observational Study

    Cristina Mussini;Patrizio Pezzotti;José M. Miró;Esteban Martinez

Frequent Co-Authors

Beatriz Grinsztejn
Beatriz Grinsztejn Oswaldo Cruz Foundation
Julio S. G. Montaner
Julio S. G. Montaner University of British Columbia
Jean-Michel Molina
Jean-Michel Molina Université Paris Cité
Sharon Walmsley
Sharon Walmsley University Health Network
Margaret Johnson
Margaret Johnson The Royal Free Hospital
Eduardo Gotuzzo
Eduardo Gotuzzo Instituto de Medicina Tropical Alexander von Humboldt
Anne-Mieke Vandamme
Anne-Mieke Vandamme Rega Institute for Medical Research
Jose R. Arribas
Jose R. Arribas Hospital Universitario La Paz
José M. Gatell
José M. Gatell University of Barcelona
Lynn Morris
Lynn Morris University of the Witwatersrand

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology in the USA opens doors to a variety of career paths, many of which can be pursued through related online degrees. For those with unique challenges, options like degrees for felons provide accessible educational opportunities tailored to diverse backgrounds.

Healthcare roles linked to microbiology, such as becoming a functional medicine nurse practitioner, combine specialized knowledge of pathogens with patient care. Online programs supporting such careers enable students to gain essential skills remotely, balancing education with real-world demands.

Beyond clinical roles, microbiology graduates may explore allied areas like medical coding and health data management. Certified Professional Coders enjoy competitive salaries, as highlighted under cpc salary insights, making certification a valuable complement to scientific expertise.

Additionally, a health information management bachelor degree salary reflects the strong earning potential in managing health data systems, crucial to modern microbiology research and healthcare services.

Best Scientists Citing Pedro Cahn

Trending Scientists

Recently Published Articles